CN114173771A - 用于治疗眼部蛋白质聚集疾病的药理学试剂 - Google Patents

用于治疗眼部蛋白质聚集疾病的药理学试剂 Download PDF

Info

Publication number
CN114173771A
CN114173771A CN202080054595.2A CN202080054595A CN114173771A CN 114173771 A CN114173771 A CN 114173771A CN 202080054595 A CN202080054595 A CN 202080054595A CN 114173771 A CN114173771 A CN 114173771A
Authority
CN
China
Prior art keywords
alkyl
radical
group
hydrogen
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080054595.2A
Other languages
English (en)
Chinese (zh)
Inventor
斯里达尔·戈文达·普拉萨德
马歇尔·克拉克·彼得曼
桑托什·辛哈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxair Pharmaceutical Co
Original Assignee
Praxair Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxair Pharmaceutical Co filed Critical Praxair Pharmaceutical Co
Publication of CN114173771A publication Critical patent/CN114173771A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080054595.2A 2019-05-31 2020-06-01 用于治疗眼部蛋白质聚集疾病的药理学试剂 Pending CN114173771A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855560P 2019-05-31 2019-05-31
US62/855,560 2019-05-31
PCT/US2020/035592 WO2020243720A1 (en) 2019-05-31 2020-06-01 Pharmacological agents for treating protein aggregation diseases of the eye

Publications (1)

Publication Number Publication Date
CN114173771A true CN114173771A (zh) 2022-03-11

Family

ID=73553335

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080054595.2A Pending CN114173771A (zh) 2019-05-31 2020-06-01 用于治疗眼部蛋白质聚集疾病的药理学试剂

Country Status (8)

Country Link
US (1) US20220241247A1 (enExample)
EP (1) EP3976017A4 (enExample)
JP (1) JP2022534420A (enExample)
CN (1) CN114173771A (enExample)
BR (1) BR112021024151A2 (enExample)
CA (1) CA3141998A1 (enExample)
MX (1) MX2021014682A (enExample)
WO (1) WO2020243720A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115298168A (zh) * 2020-01-28 2022-11-04 普罗泰格生物制药公司 用于稳定甲状腺素运载蛋白和抑制甲状腺素运载蛋白错误折叠的化合物、组合物和方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
WO2023278604A1 (en) * 2021-06-29 2023-01-05 Plex Pharmaceuticals, Inc. Pharmacological agents for treating ophthalmic diseases
WO2023009585A2 (en) * 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198598A (zh) * 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
CN103889407A (zh) * 2011-10-24 2014-06-25 索姆创新生物技术公司 用于甲状腺素运载蛋白相关的淀粉样变性的新疗法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013038351A1 (en) * 2011-09-16 2013-03-21 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9169214B2 (en) * 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
JP2016514091A (ja) * 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
BR112015021836A2 (pt) * 2013-03-08 2017-07-18 Allergan Inc conjugados de antibióticos diretamente ligados com drogas esteroides
US9789091B2 (en) * 2013-03-14 2017-10-17 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
US11872236B2 (en) * 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198598A (zh) * 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
WO2011116123A1 (en) * 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
CN103889407A (zh) * 2011-10-24 2014-06-25 索姆创新生物技术公司 用于甲状腺素运载蛋白相关的淀粉样变性的新疗法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
1222800-98-7，STN结构检索, pages 1, Retrieved from the Internet <URL:registry> *
A. C. MARTINS等: "Ocular Manifestations and Therapeutic Options in Patients with Familial Amyloid Polyneuropathy: A Systematic Review", BIOMED RESEARCH INTERNATIONAL, pages 1 - 10 *
ARIEL M. ALPERSTEIN等: "Amyloid found in human cataracts with twodimensional infrared spectroscopy", PNAS LATEST ARTICLES, pages 1 - 6 *
LEAH N. MAKLEY等: "Pharmacological chaperone for a-crystallin partially restores transparency in cataract models", SCIENCEMAG.ORG, vol. 350, pages 674 - 677 *
MELO BEIRÃO等: "Anticipation of presbyopia in Portuguese familial amyloidosis ATTR V30M", AMYLOID, vol. 18, no. 3, pages 92 - 97, XP009532005, DOI: 10.3109/13506129.2011.576719 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115298168A (zh) * 2020-01-28 2022-11-04 普罗泰格生物制药公司 用于稳定甲状腺素运载蛋白和抑制甲状腺素运载蛋白错误折叠的化合物、组合物和方法

Also Published As

Publication number Publication date
WO2020243720A9 (en) 2021-02-04
MX2021014682A (es) 2022-04-06
EP3976017A4 (en) 2023-06-14
WO2020243720A1 (en) 2020-12-03
US20220241247A1 (en) 2022-08-04
JP2022534420A (ja) 2022-07-29
CA3141998A1 (en) 2020-12-03
BR112021024151A2 (pt) 2022-02-08
EP3976017A1 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
US20220241247A1 (en) Pharmacological agents for treating protein aggregation diseases of the eye
JP4234430B2 (ja) チオールを含むｎａａｌａｄアーゼ抑制物質
CA3032609A1 (en) Aldehyde trapping compounds and methods of use thereof
JP2019532029A (ja) アルデヒド補足化合物およびその使用
JP7532259B2 (ja) 眼疾患治療薬剤
EA018922B1 (ru) Модулирующие сиртуин соединения
CN104193740A (zh) 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
EP2377860A1 (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW201444860A (zh) 脲嘧啶核苷衍生物、組合物及使用方法
JP2021181473A (ja) 精神病性障害を治療するための方法および組成物
JP4832897B2 (ja) エステル誘導体及びその医薬用途
EP3716981A1 (en) Compounds for treating near vision disorders
JPS59176270A (ja) 眼内圧上昇の局所治療用ベンゾチアゾ−ル−２−スルホンアミド誘導体
WO2020213693A1 (ja) リポ酸プロドラッグ
EP4501918A1 (en) 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient
JP2021520413A (ja) 眼科的状態のための療法
US7511036B2 (en) Dihydrothiazine prodrugs of thiazolium agents
TW202602459A (zh) Gpx4抑制劑與抗衰老化合物及其用途
JP2010235535A (ja) ＰＰＡＲαアゴニストを有効成分として含有する網脈絡膜疾患の予防又は治療剤
JP7158466B2 (ja) てんかん、神経変性疾患、及び他のｃｎｓ疾患を治療するための化合物
WO2026107201A1 (en) Non-retinoid pharmacochaperones and uses thereof
TW202330510A (zh) 對老花眼等之治療或預防有用之含硫化合物
TW202537626A (zh) 含磷ｂｃｌ抑制劑及抗衰老化合物及其用途
EP2488176B1 (en) Rhodacyanine derivative and pharmaceutical composition for treating leishmaniasis
JP2002255800A (ja) 血管新生阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220311

WD01 Invention patent application deemed withdrawn after publication